Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?
Eli Lilly (NYSE: LLY) shares have soared more than 87% over the past year, making this player look more like a growth stock than a slower-paced but steady pharmaceutical stock. Lilly sells a broad range of medicines, but what lately has struck the fancy of investors -- and doctors and patients -- is the company's weight loss portfolio.
Doctors prescribe Lilly's Mounjaro and Zepbound to help patients manage their weight, and the results have been fantastic. This has helped Lilly's revenue soar -- and the share price followed. Though Lilly shares the market with rival big pharma Novo Nordisk, both companies are excelling, with demand for their products outstripping supply.
But could one particular trend represent a threat to Lilly's dominance?
Source Fool.com
